HPS-121 - Drug use assessment of naldemedine

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-121
• By: LI, Min-fen (Department Of Pharmacy, E-da Hospital, China Taiwan)
• Co-author(s): Ms Min-fen Li (Department Of Pharmacy, E-da Hospital, Kaohsiung, China Taiwan)
  Mr. Yung-Chia Hsu (Department Of Pharmacy, E-da Hospital, Kaohsiung, China Taiwan)
  
• Abstract:

  Introduction
  Naldemedine is an FDA (U.S. Food and Drug Administration) approved Peripherally- Acting Mu-Opioid Receptor Antagonists (PAMORA). Treatment of Opioid-Induced Constipation (OIC) in adults. New drug for type μ, δ, κ opioid receptor antagonist effect, which improves constipation caused by opiates, mainly acts on type μ opioid..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login